Epstein-Barr virus and systemic lupus erythematosus

Area of Science:

• Immunology
• Virology
• Rheumatology

Background:

• The exact cause of systemic lupus erythematosus (SLE) remains unclear, but its fluctuating disease activity suggests a potential role for latent infections.
• Epstein-Barr virus (EBV) has long been implicated in SLE pathogenesis due to its ability to cycle between latent and lytic phases.

Purpose of the Study:

• To review EBV immunobiology and its connection to SLE pathogenesis.
• To illustrate how uncontrolled EBV reactivation may serve as a disease mechanism in SLE.

Main Methods:

• Review of existing studies on EBV in SLE patients.
• Analysis of EBV viral load, gene expression, T-cell responses, and antibody levels.

Main Results:

• SLE patients exhibit increased EBV viral load and abnormal expression of viral lytic genes.
• Impaired EBV-specific T-cell responses and elevated levels of EBV-directed antibodies, particularly IgA, are observed in SLE.
• Reduced T-cell control over EBV may lead to frequent reactivation and expression of lytic antigens.

Conclusions:

• Uncontrolled EBV reactivation is a potential disease mechanism in SLE.
• EBV reactivation contributes to enhanced apoptosis, cellular waste, and the development of autoantibodies.
• Defective cell-mediated immunity in SLE patients may impair EBV control, promoting disease activity.